MicroRNA biomarkers may detect CNS disorders; MDxHealth teams up with Pfizer;

> The identification of microRNA biomarkers in the cerebrospinal fluid may become an important method for the diagnosis of primary central nervous system disorders. Article

> MDxHealth teams up with Pfizer, Newcastle University and CRT to identify and develop a biomarker predicting response to their drug candidate for PARP inhibition, which promises to treat ovarian and breast cancers. MDxHealth release

> Avantra Biosciences, based in Woburn, MA, has shipped its first Q400 Biomarker Workstation and Angio Qx BioChip Immunoassay. The system provides quantitative protein biomarker results for 10 analytes in less than an hour, requiring less than five minutes for sample preparation, according to a company release. Story

> British scientists study biomarkers for predicting the efficacy of bevacizumab (Avastin), which is a monoclonal antibody against the protein vascular endothelial growth factor A (VEGF). VEGF is over-expressed in many tumor types. Report

> A new tool for finding allergy biomarkers. Item

> An update on breast cancer biomarkers. Report

Suggested Articles

A decade-long study found that patients with early breast cancer may be spared radiation procedures that span the whole breast.

A cell therapy for Parkinson’s disease starts out simple, but quickly gets complicated with the potential for immune responses and cancer mutations.

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.